Remove Drug Development Remove Marketing Remove Pharma Companies
article thumbnail

How AI will reshape pharma by 2025

Drug Target Review

Artificial intelligence (AI) has revolutionised many industries, yet its adoption in pharmaceutical drug development has been notably slower. For years, AI and machine learning (ML) were often dismissed as little more than advanced statistics with little practical value in drug development.

article thumbnail

Best CDMO Practices for Startups: Navigating the Complex World of Contract Development and Manufacturing

Drug Patent Watch

Navigating the complex landscape of drug development and manufacturing can be a daunting task. Enter the Contract Development and Manufacturing Organization (CDMO) a lifeline for many startups looking to bring their innovative therapies to market. A: It’s never too early to start considering CDMO partnerships.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Tackling complex manufacturing challenges in modern drug development

Drug Target Review

With a particular focus on biologics, cell, and gene therapies, Galbraiths work is centred on equipping drug developers with the tools, insights, and support needed to advance their therapies from concept to clinic. Harnessing emerging technologies The rapid pace of technological innovation is reshaping the landscape of drug discovery.

article thumbnail

Pharma Contract Sales Outlook 2025–2030: Multilingual Teams Drive Global Expansion

The Pharma Data

Global Pharmaceutical Contract Sales Outsourcing Market to Reach $24.8 Billion by 2030: Strategic Insights, Regional Trends, and Technological Shifts Reshaping the Landscape The global pharmaceutical contract sales outsourcing (CSO) market is entering a transformative phase, with its value expected to grow from $17.3 In the U.S.,

article thumbnail

Key Challenges of Specialty Pharma Drug Development Project Management

thought leadership

Specialty pharma companies are focused on developing drugs for niche markets, such as rare diseases , cancer, and other complex conditions. These drugs often require significant investment in research and development, and their development requires careful project management.

article thumbnail

Why Do Pharma Companies Outsource to CROs?

Vial

To address these challenges, many companies outsource their clinical trials to contract research organizations (CROs) with established protocols, global reach, and therapeutic area expertise1. According to the 2022 Polaris Market Research Report , the global clinical trials outsourcing market reached USD 38.11

article thumbnail

Fierce Biotech Week

Fierce BioTech

Fierce Biotech Week Fierce Biotech Week features insights from C-suite and executive leadership at biotech, mid-sized and large pharma companies on emerging trends and market dynamics that will help effectively prioritize R&D spend, optimize drug development and clinical operations, and navigate capital raising and partnering deals.